Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer

Authors' Affiliation: Division of Population Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
Clinical Cancer Research (Impact Factor: 8.19). 09/2008; 14(15):4935-42. DOI: 10.1158/1078-0432.CCR-08-0958
Source: PubMed

ABSTRACT Activation of COX-2 and inhibition of PPARgamma have been observed in human and animal models of breast cancer. Both inhibition of COX-2 and activation of PPARgamma can inhibit proliferation of breast cancer cells in vitro. Here, we examine the effects of the COX-2 inhibitor celecoxib and the PPARgamma agonist N-(9-fluorenyl-methyloxycarbonyl)-l-leucine (F-L-Leu) on mouse breast tumor cells in vitro and in vivo.
We created and characterized a mouse mammary adenocarcinoma cell (MMAC-1) line from C3 (1)-SV40 tumor antigen mice to study COX-2 and PPARgamma expression and response to celecoxib and F-L-Leu in vitro. To study the in vivo effects, C3 (1)-SV40 tumor antigen mice were given either control diet or diets containing three different concentrations of celecoxib and F-L-Leu as well as a combination of both agents. Mice were then followed for tumor formation up to 1 year.
MMAC-1 cells express both COX-2 and PPARgamma mRNA and exhibited cooperative growth inhibition with a combination of celecoxib and F-L-Leu. In mice, the median age of death due to mammary tumors was significantly delayed in celecoxib-treated animals at all three concentrations but was not significantly affected by F-L-Leu treatment alone. A combination of celecoxib and F-L-Leu was significantly more effective than celecoxib alone.
Our findings suggest that a combination of a COX-2 inhibitor and PPARgamma agonist can delay breast cancer in a mouse model and suggest that these agents should be studied in the context of human populations with high breast cancer risk.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Extra virgin olive oil (EVOO) has demonstrated great oncostatic and antiinflammatory properties. Nowadays, it is clear that unsaponifiable fraction (UF) as well as other minor EVOO components have a key role in these beneficial effects. The present study was designed to evaluate UF effect in HT-29 human colon adenocarcinoma cells. Cell growth and viability assays were determined by sulphorhodamine B test at different time points (24, 48, and 72 h). The proapoptotic effect was evaluated by flow cytometric studies and different protein expression were determined by immunoblotting. UF μg/mL concentrations' range significantly reduced the growth of HT-29 cell line. Moreover UF induced intrinsic apoptotic pathway in HT-29 human colon adenocarcinoma cells through PPARγ and NFκB signaling pathways coming up to COX-2 downregulation and modulating p53 suppressor protein levels. The results suggest that UF of EVOO may exert an important role in the anticancer effect of EVOO and provide a natural resource for the prevention or treatment of human colon cancer.
    Nutrition and Cancer 08/2013; 65(6):908-18. DOI:10.1080/01635581.2013.806674 · 2.47 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The inflammatory response is an immune response of the body when exposed to internal and external stimuli. Cyclooxygenases (COX) are major inflammatory mediators implicated in inflammation. COX-2 is reported to be involved in neuroinflammation. Moreover, 15-Deoxy-D (12,14)-prostaglandin J2 (15d-PGJ2), an endogenous ligand of peroxisome proliferator-activated receptor gamma (PPAR-γ), has been demonstrated to have anti-inflammatory actions. In this study, we investigated whether co-therapy of a selective COX-2 inhibitor NS-398 and 15d-PGJ2 as a PPAR-γ ligand could exert additional neuroprotective effects in rat pheochromocytoma (PC12) cells. Our findings showed that 15d-PGJ2 and NS-398 suppress the apoptotic pathway in PC12 cells exposed to H(2)O(2) by attenuation of the Bax/Bcl-2 ratio. This effect was mediated through PPAR-γ, as it was reversed by GW9662 (a PPAR-γ inhibitor). Also, 15d-PGJ2 and NS-398 induced the Nrf2 signaling pathway and decreased NF-κB level in a PPAR-γ-dependent manner. We found that coadministration of a selective COX-2 inhibitor and a PPAR-γ ligand in PC12 cells has equal neuroprotective effect compared to their effects when used separately. Considering the higher affinity of 15d-PGJ2 for PPAR-γ than NS-398, it seems that the observed neuroprotection of this combination therapy was from 15d-PGJ2.
    Journal of Molecular Neuroscience 11/2012; 49(1). DOI:10.1007/s12031-012-9903-5 · 2.76 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Increased production of the pro-inflammatory enzyme cyclooxygenase-2 (Cox-2) and altered expression and activity of peroxisome proliferator-activated receptor γ (PPARγ) have been observed in many malignancies. Both the PPARγ ligands and the Cox-2 inhibitors possess anti-inflammatory and anti-neoplastic effects in vitro and have been assessed for their therapeutic potential in several pre-clinical and clinical studies. Recently, multiple interactions between PPARγ and Cox-2 signaling pathways have been revealed. Understanding of the cross-talk between PPARγ and Cox-2 might provide important novel strategies for the effective treatment and/or prevention of cancer. This article summarizes recent achievements involving the functional interactions between the PPARγ and Cox-2 signaling pathways and discusses the implications of such interplay for clinical use.
    Experimental and therapeutic medicine 01/2010; 1(2):257-264. DOI:10.3892/etm_00000040 · 0.94 Impact Factor

Full-text (2 Sources)

Available from
May 19, 2014